{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:57:15Z","timestamp":1788411435866,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropeptides"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.npep.2025.102538","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:17:00Z","timestamp":1752571020000},"page":"102538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Neuropeptide Y as a multifaceted modulator of neuroplasticity, Neuroinflammation, and HPA axis dysregulation: Perceptions into treatment-resistant depression"],"prefix":"10.1016","volume":"112","author":[{"given":"Priyanka","family":"Singanwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Tatode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Qutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Taksande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Umekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Premchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.npep.2025.102538_bb0005","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1634\/stemcells.2008-0056","article-title":"Neuropeptide Y promotes neurogenesis in murine subventricular zone","volume":"26","author":"Agasse","year":"2008","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/neurolint15010009","article-title":"Inflammation and treatment-resistant depression from clinical to animal study: A possible link?","volume":"15","author":"Almutabagani","year":"2023","journal-title":"Neurol. Int."},{"key":"10.1016\/j.npep.2025.102538_bb0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jad.2022.09.011","article-title":"Understanding treatment-resistant depression using \u201comics\u201d techniques: A systematic review","volume":"318","author":"Amasi-Hartoonian","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0278-5846(94)90057-4","article-title":"Fluoxetine efficacy in treatment resistant depression","volume":"18","author":"Amsterdam","year":"1994","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.npep.2025.102538_bb0025","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.yhbeh.2015.05.018","article-title":"Neuropeptide Y administration reverses tricyclic antidepressant treatment-resistant depression induced by ACTH in mice","volume":"73","author":"Antunes","year":"2015","journal-title":"Horm. Behav."},{"issue":"8","key":"10.1016\/j.npep.2025.102538_bb0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/cells13080669","article-title":"Enhancing cognitive functions and neuronal growth through NPY1R agonist and ketamine co-administration: evidence for NPY1R-TrkB Heteroreceptor complexes in rats","volume":"13","author":"Arrabal-G\u00f3mez","year":"2024","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.npep.2025.102538_bb0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jagp.2019.10.012","article-title":"An evaluation of the clinical and economic burden among older adult Medicare-covered beneficiaries with treatment-resistant depression","volume":"28","author":"Benson","year":"2020","journal-title":"Am. J. Geriatr. Psychiatr."},{"issue":"3","key":"10.1016\/j.npep.2025.102538_bb0040","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.nano.2016.11.009","article-title":"An in vitro and in vivo study of peptide-functionalized nanoparticles for brain targeting: the importance of selective blood\u2013brain barrier uptake","volume":"13","author":"Bode","year":"2017","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.npep.2025.102538_bb0045","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bph.15753","article-title":"Novel drug developmental strategies for treatment-resistant depression","volume":"179","author":"Borb\u00e9ly","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.npep.2025.102538_bb0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00787-019-01341-5","article-title":"A systematic review of interventions for treatment resistant major depressive disorder in adolescents","volume":"29","author":"Boylan","year":"2020","journal-title":"Eur. Child Adolesc. Psychiatry"},{"issue":"11","key":"10.1016\/j.npep.2025.102538_bb0055","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/emmm.201000100","article-title":"Therapeutic potential of neuropeptide Y (NPY) receptor ligands","volume":"2","author":"Brothers","year":"2010","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0060","first-page":"5048616","article-title":"Neuropeptides and microglial activation in inflammation, pain, and neurodegenerative diseases","volume":"2017","author":"Carniglia","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"11","key":"10.1016\/j.npep.2025.102538_bb0065","article-title":"Neuroplasticity and the biological role of brain derived neurotrophic factor in the pathophysiology and Management of Depression","volume":"12","author":"Chakrapani","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.2018.66","article-title":"Treatment-resistant depression and peripheral C-reactive protein","volume":"214","author":"Chamberlain","year":"2019","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0075","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/npp.2011.230","article-title":"The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder","volume":"37","author":"Cohen","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2025.102538_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjpmh.2023.06.001","article-title":"Latin American consensus recommendations for the management and treatment of patients with treatment-resistant depression (TRD)","author":"Corral","year":"2023","journal-title":"Spanish J. Psychiatr Mental Health."},{"issue":"3","key":"10.1016\/j.npep.2025.102538_bb0085","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hipo.20765","article-title":"Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis","volume":"21","author":"Decressac","year":"2011","journal-title":"Hippocampus"},{"key":"10.1016\/j.npep.2025.102538_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110349","article-title":"Neuropeptide Y Y2 and Y5 receptors as potential targets for neuroprotective and antidepressant therapies: evidence from preclinical studies","volume":"111","author":"Domin","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.npep.2025.102538_bb0095","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00213-016-4495-3","article-title":"Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence","volume":"234","author":"Domin","year":"2016","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0100","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41598-021-82339-5","article-title":"Neuropeptide Y (NPY) intranasal delivery alleviates Machado\u2013Joseph disease","volume":"11","author":"Duarte-Neves","year":"2021","journal-title":"Sci. Rep."},{"issue":"6103","key":"10.1016\/j.npep.2025.102538_bb0105","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.npep.2025.102538_bb0110","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/apha.12445","article-title":"The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour","volume":"213","author":"Farzi","year":"2015","journal-title":"Acta Physiol (Oxford)"},{"issue":"8","key":"10.1016\/j.npep.2025.102538_bb0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.npep.2025.102538_bb0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.biopsych.2019.07.012","article-title":"The biology of human resilience: opportunities for enhancing resilience across the life span","volume":"86","author":"Feder","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"53","key":"10.1016\/j.npep.2025.102538_bb0125","doi-asserted-by":"crossref","first-page":"41921","DOI":"10.1074\/jbc.M110.164020","article-title":"Neuropeptide y modulation of interleukin-1\u03b2 (IL-1\u03b2)-induced nitric oxide production in microglia","volume":"285","author":"Ferreira","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000441521","article-title":"Inflammatory cytokines and antipsychotic-induced weight gain: review and clinical implications","volume":"2","author":"Fonseka","year":"2016","journal-title":"Complex Psychiatry"},{"issue":"8","key":"10.1016\/j.npep.2025.102538_bb0135","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1111\/j.1476-5381.2012.01939.x","article-title":"A role for neuropeptide y in the gender-specific gastrointestinal, corticosterone and feeding responses to stress","volume":"166","author":"Forbes","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"12","key":"10.1016\/j.npep.2025.102538_bb0140","first-page":"5917","article-title":"Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines","volume":"15","author":"Fu","year":"2023","journal-title":"Aging (Albany NY)"},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s41669-021-00306-2","article-title":"Real-world treatment patterns, outcomes, resource utilization and costs in treatment-resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium","volume":"6","author":"Gillain","year":"2022","journal-title":"PharmacoEconomics \u2013 Open"},{"issue":"4","key":"10.1016\/j.npep.2025.102538_bb0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.npep.2004.05.002","article-title":"The NPY system in stress, anxiety and depression","volume":"38","author":"Heilig","year":"2004","journal-title":"Neuropeptides"},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/j.2040-4603.2016.tb00694.x","article-title":"Regulation of the hypothalamic-pituitary-adrenocortical stress response","volume":"6","author":"Herman","year":"2016","journal-title":"Compr. Physiol."},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/npr2.12304","article-title":"Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study","volume":"43","author":"Hidese","year":"2023","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.npep.2025.102538_bb0165","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.expneurol.2016.07.002","article-title":"Understanding resilience: new approaches for preventing and treating PTSD","volume":"284","author":"Horn","year":"2016","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-020-02935-z","article-title":"Investigation of early and lifetime clinical features and comorbidities for the risk of developing treatment-resistant depression in a 13-year nationwide cohort study","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.npep.2025.102538_bb0175","series-title":"Neuroprotection in Autism, Schizophrenia and Alzheimer\u2019s Disease","first-page":"145","article-title":"Neuroprotective roles of neurotrophic growth factors in mood disorders","author":"Jiang","year":"2020"},{"key":"10.1016\/j.npep.2025.102538_bb0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jad.2018.06.045","article-title":"The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature","volume":"242","author":"Johnston","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"9","key":"10.1016\/j.npep.2025.102538_bb0185","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/nm.2886","article-title":"Decreased expression of synapse-related genes and loss of synapses in major depressive disorder","volume":"18","author":"Kang","year":"2012","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1460-9568.2008.06306.x","article-title":"Behavioural profile of a new mouse model for NPY deficiency","volume":"28","author":"Karl","year":"2008","journal-title":"Eur. J. Neurosci."},{"issue":"8","key":"10.1016\/j.npep.2025.102538_bb0195","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3390\/ijms25084511","article-title":"Mechanisms involved in the link between depression, antidepressant treatment, and associated weight change","volume":"25","author":"Kukucka","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.npep.2025.102538_bb0200","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/bs12080262","article-title":"Anxiety and depression: what do we know of neuropeptides?","volume":"12","author":"Kupcova","year":"2022","journal-title":"Behav. Sci."},{"issue":"9","key":"10.1016\/j.npep.2025.102538_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3928\/02793695-20210816-01","article-title":"Treatment-resistant depression approaches to treatment","volume":"59","author":"Kverno","year":"2021","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"issue":"4","key":"10.1016\/j.npep.2025.102538_bb0210","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0893-133X(99)00134-7","article-title":"Cytokine production and treatment response in major depressive disorder","volume":"22","author":"Lanquillon","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1523\/JNEUROSCI.2599-16.2016","article-title":"Endogenously released neuropeptide Y suppresses hippocampal short-term facilitation and is impaired by stress-induced anxiety","volume":"37","author":"Li","year":"2017","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.npep.2025.102538_bb0220","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/ijnp\/pyaa054","article-title":"A randomized controlled trial of intranasal neuropeptide Y in patients with major depressive disorder","volume":"23","author":"Math\u00e9","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"SEPTEMBER","key":"10.1016\/j.npep.2025.102538_bb0225","first-page":"54","article-title":"Differential regulation of neuropeptide Y in the amygdala and prefrontal cortex during recovery from chronic variable stress","volume":"5","author":"McGuire","year":"2011","journal-title":"Front. Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.npep.2025.102538_bb0230","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: from evolutionary imperative to modern treatment target","volume":"16","author":"Miller","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/jnt6020010","article-title":"Nanotheranostics revolutionizing gene therapy: emerging applications in gene delivery enhancement","volume":"Vol. 6","author":"Moghimi","year":"2025","journal-title":"J. Nanotheranostics"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2011.06.030","article-title":"Role of neuropeptide Y Y\u2081 and Y\u2082 receptors on behavioral despair in a rat model of depression with co-morbid anxiety","volume":"62","author":"Morales-Medina","year":"2012","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.npep.2025.102538_bb0250","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1517\/14728214.2015.1049996","article-title":"Emerging drugs for the treatment of anxiety","volume":"20","author":"Murrough","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0255","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40265-023-01983-5","article-title":"A neuroanatomic and pathophysiologic framework for novel pharmacological approaches to the treatment of post-traumatic stress disorder","volume":"84","author":"Norred","year":"2024","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.npep.2025.102538_bb0260","article-title":"Hypothalamic-pituitary-adrenal (HPA) Axis: unveiling the potential mechanisms involved in stress-induced Alzheimer\u2019s disease and depression","volume":"16","author":"P, S., & Vellapandian, C.","year":"2024","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.npep.2025.102538_bb0265","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1177\/0269881109348171","article-title":"Evidence from knockout mice that neuropeptide-Y Y2 and Y4 receptor signalling prevents long-term depression-like behaviour caused by immune challenge","volume":"24","author":"Painsipp","year":"2009","journal-title":"J. Psychopharmacol. (Oxford, England)"},{"issue":"11","key":"10.1016\/j.npep.2025.102538_bb0270","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.psyneuen.2013.06.020","article-title":"Region-specific alterations in glucocorticoid receptor expression in the postmortem brain of teenage suicide victims","volume":"38","author":"Pandey","year":"2013","journal-title":"Psychoneuroendocrinology"},{"issue":"8","key":"10.1016\/j.npep.2025.102538_bb0275","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41380-024-02468-x","article-title":"Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial","volume":"29","author":"Papakostas","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.npep.2025.102538_bb0280","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jad.2024.04.017","article-title":"Treatment resistant late-life depression: A narrative review of psychosocial risk factors, non-pharmacological interventions, and the role of clinical phenotyping","volume":"356","author":"Patrick","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0285","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s11033-019-05129-3","article-title":"The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression","volume":"47","author":"Pitsillou","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/j.npep.2025.102538_bb0290","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3892\/etm.2021.10565","article-title":"Neuroplasticity and depression: rewiring the brain\u2019s networks through pharmacological therapy (review)","volume":"22","author":"R\u0103dulescu","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"6","key":"10.1016\/j.npep.2025.102538_bb0295","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0006-3223(99)00185-7","article-title":"Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD","volume":"47","author":"Rasmusson","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.npep.2025.102538_bb0300","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0893-133X(01)00403-1","article-title":"The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test","volume":"26","author":"Redrobe","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2025.102538_bb0305","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.npep.2015.09.008","article-title":"Neuropeptide Y: A stressful review","volume":"55","author":"Reichmann","year":"2015","journal-title":"Neuropeptides"},{"issue":"5","key":"10.1016\/j.npep.2025.102538_bb0310","doi-asserted-by":"crossref","first-page":"636","DOI":"10.2174\/1570159X13666150630175044","article-title":"Beyond monoamines-novel targets for treatment-resistant depression: A comprehensive review","volume":"13","author":"Rosenblat","year":"2015","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0315","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0004867418808585","article-title":"Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive","volume":"53","author":"Rush","year":"2019","journal-title":"Austr New Zealand J. Psychiatr."},{"issue":"6","key":"10.1016\/j.npep.2025.102538_bb0320","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/mp.2012.101","article-title":"Neuropeptide Y and posttraumatic stress disorder","volume":"18","author":"Sah","year":"2012","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10253890600557315","article-title":"The role of neuropeptide Y in the amygdala on corticotropin-releasing factor receptor-mediated behavioral stress responses in the rat","volume":"9","author":"Sajdyk","year":"2006","journal-title":"Stress"},{"issue":"12","key":"10.1016\/j.npep.2025.102538_bb0330","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the value of gene therapy and enhancing patient access to transformative treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0335","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/npp.2014.261","article-title":"Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders","volume":"40","author":"Sanacora","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.npep.2025.102538_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.ssmmh.2022.100081","article-title":"Treatment-resistant depression reconsidered","volume":"2","author":"Schroder","year":"2022","journal-title":"SSM \u2013 Mental Health"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0345","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.euroneuro.2013.11.007","article-title":"Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model","volume":"24","author":"Serova","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.npep.2025.102538_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110428","article-title":"Effect of depression and suicidal behavior on neuropeptide Y (NPY) and its receptors in the adult human brain: A postmortem study","volume":"112","author":"Sharma","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.npep.2025.102538_bb0355","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11920-019-1075-3","article-title":"Microbiome and mental health, specifically as it relates to adolescents","volume":"21","author":"Simkin","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"issue":"6","key":"10.1016\/j.npep.2025.102538_bb0360","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hipo.20415","article-title":"NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning","volume":"18","author":"S\u00f8rensen","year":"2008","journal-title":"Hippocampus"},{"issue":"4","key":"10.1016\/j.npep.2025.102538_bb0365","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1074\/jbc.M115.678185","article-title":"Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer disease","volume":"291","author":"Spencer","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0370","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1017\/neu.2021.36","article-title":"Sirtuins and neuropeptide y downregulation in Flinders sensitive line rat model of depression","volume":"34","author":"Stiernborg","year":"2022","journal-title":"Acta Neuropsychiatrica"},{"issue":"10","key":"10.1016\/j.npep.2025.102538_bb0375","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","article-title":"Inflammation and clinical response to treatment in depression: A meta-analysis","volume":"25","author":"Strawbridge","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.npep.2025.102538_bb0380","doi-asserted-by":"crossref","first-page":"823","DOI":"10.18553\/jmcp.2019.25.7.823","article-title":"Economic burden of treatment-resistant depression on the U.S.Health care system","volume":"25","author":"Sussman","year":"2019","journal-title":"J. Managed Care Specialty Pharmacy"},{"issue":"6","key":"10.1016\/j.npep.2025.102538_bb0385","first-page":"2689","article-title":"Dysregulation of adult hippocampal neuroplasticity in major depression: pathogenesis and therapeutic implications","volume":"27","author":"Tartt","year":"2022","journal-title":"Molecular Psychiatry 2022 27:6"},{"key":"10.1016\/j.npep.2025.102538_bb0390","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.npep.2015.09.007","article-title":"The role of neuropeptide Y in fear conditioning and extinction","volume":"55","author":"Tasan","year":"2016","journal-title":"Neuropeptides"},{"issue":"5","key":"10.1016\/j.npep.2025.102538_bb0395","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/jnr.24589","article-title":"Neuropeptide Y in PTSD, MDD, and chronic stress: A systematic review and meta-analysis","volume":"98","author":"Tural","year":"2020","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.npep.2025.102538_bb0400","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.npep.2025.102538_bb0405","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1523\/JNEUROSCI.4955-13.2016","article-title":"Neuropeptide Y impairs retrieval of extinguished fear and modulates excitability of neurons in the Infralimbic prefrontal cortex","volume":"36","author":"Vollmer","year":"2016","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.npep.2025.102538_bb0410","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (sustain-2)","volume":"81","author":"Wajs","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.npep.2025.102538_bb0415","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000517074","article-title":"Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: A randomized clinical trial","volume":"90","author":"Wilkinson","year":"2021","journal-title":"Psychother. Psychosom."},{"issue":"11","key":"10.1016\/j.npep.2025.102538_bb0420","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14728222.2011.628314","article-title":"Central functions of neuropeptide Y in mood and anxiety disorders","volume":"15","author":"Wu","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"issue":"7702","key":"10.1016\/j.npep.2025.102538_bb0425","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41586-018-0046-x","article-title":"Structural basis of ligand binding modes at the neuropeptide y Y1 receptor","volume":"556","author":"Yang","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.npep.2025.102538_bb0430","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.00082","article-title":"The role of BDNF on neural plasticity in depression","volume":"14","author":"Yang","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.npep.2025.102538_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.629003","article-title":"Electro-acupuncture attenuates chronic stress responses via up-regulated central NPY and GABAA receptors in rats","volume":"14","author":"Yang","year":"2021","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0440","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/biomedicines10020343","article-title":"Potentials of neuropeptides as therapeutic agents for neurological diseases","volume":"10","author":"Yeo","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.npep.2025.102538_bb0445","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The prevalence and National Burden of treatment-resistant depression and major depressive disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.npep.2025.102538_bb0450","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1749-6632.1995.tb44683.x","article-title":"Neuropeptide Y. A novel sympathetic stress hormone and more","volume":"771","author":"Zukowska-Grojec, Z.","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Neuropeptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417925000381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0143417925000381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T13:29:07Z","timestamp":1752758947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0143417925000381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":90,"alternative-id":["S0143417925000381"],"URL":"https:\/\/doi.org\/10.1016\/j.npep.2025.102538","relation":{},"ISSN":["0143-4179"],"issn-type":[{"value":"0143-4179","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropeptide Y as a multifaceted modulator of neuroplasticity, Neuroinflammation, and HPA axis dysregulation: Perceptions into treatment-resistant depression","name":"articletitle","label":"Article Title"},{"value":"Neuropeptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.npep.2025.102538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102538"}}